Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Summary From the First Kidney Cancer Research Summit, September 12–13, 2019: A Focus on Translational Research

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa064Source: DataRank Database

Summary From the First Kidney Cancer Research Summit, September 12–13, 2019: A Focus on Translational Research is a research paper published in JNCI Journal of the National Cancer Institute (2020). On theSindex it has a DataRank of 0.557. It has been cited 40 times.

N/A

0.557DataRank · unranked

Scored on demand from live citation data

Open Access40 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 3.73)OA: hybridTopics (20)Linked Datasets (14)DataCite Reuse (14)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.557

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (20)

Michael B. Atkins ORCID,Ziad Bakouny ORCID,Maria I. Carlo ORCID,Charles G. Drake ORCID,Eric Jonasch ORCID

Live enrichment

PubMed:32359162 PMC:PMC7936057 OpenAlex:https://openalex.org/W3021796372

KidneyCAN

Grant: KCRS19

KidneyCAN

Grant: EIN: 81–3352468

NCATS NIH HHS

Grant: DP2 TR002776

NCI NIH HHS

Grant: P30 CA016520

FWCI

3.73

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://academic.oup.com/jnci/article-pdf/113/3/234/36419095/djaa064.pdf

publisherhttps://academic.oup.com/jnci/article-pdf/113/3/234/36419095/djaa064.pdf

publisherhttp://academic.oup.com/jnci/advance-article-pdf/doi/10.1093/jnci/djaa064/33750563/djaa064.pdf

publisherhttp://academic.oup.com/jnci/article-pdf/113/3/234/36419095/djaa064.pdf

journalhttps://doi.org/10.1093/jnci/djaa064

Fields of Study

Renal cell carcinoma treatmentCancer Genomics and DiagnosticsRenal and related cancers

MeSH Terms

AnimalsCarcinoma, Renal CellClinical Trials as TopicHumansKidney NeoplasmsRandomized Controlled Trials as Topic

Keywords

SummitTranslational researchKidney cancerFocus (optics)CancerMedicinePolitical scienceInternal medicineGeographyPathologyCartography

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy

10.6084/m9.figshare.21130011.v1figshare

Additional file 1 of A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy

10.6084/m9.figshare.21130011figshare

Additional file 2 of A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy

10.6084/m9.figshare.21130012.v1figshare

Additional file 2 of A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy

10.6084/m9.figshare.21130012figshare

Additional file 3 of A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy

10.6084/m9.figshare.21130013.v1figshare

Additional file 3 of A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy

10.6084/m9.figshare.21130013figshare

Additional file 4 of A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy

10.6084/m9.figshare.21130014.v1figshare

Additional file 4 of A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy

10.6084/m9.figshare.21130014figshare

Additional file 5 of A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy

10.6084/m9.figshare.21130015.v1figshare

Additional file 5 of A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy

10.6084/m9.figshare.21130015figshare

Additional file 6 of A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy

10.6084/m9.figshare.21130016.v1figshare

Additional file 6 of A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy

10.6084/m9.figshare.21130016figshare

Additional file 7 of A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy

10.6084/m9.figshare.21130017.v1figshare

Additional file 7 of A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy

10.6084/m9.figshare.21130017figshare